Anticoncepción Oral en Perspectiva, Bibliografía

Dr. Álvaro Monterrosa Castro, M.D

1 Edwards L. An update and oral contraceptive options. Formulary. 2004; 39: 104 121.
2 Zabaleta A. Breviario de la Anticoncepción oral. 1974. Cartagena.
3 Profamilia. Historia de los métodos anticonceptivos. Cuadernillo estudiantil. Centro documentación Profamilia. Bogotá. 1993.
4 Monterrosa A. Anticonceptivos orales combinados Tercera Edición. Editorial Impresos Calidad. Bogotá. 2003.
5 Monterrosa A. Anticoncepción hormonal. EN: Caraballo J, Parra E, Taylor H. Memorias del 1º Curso de actualización en Ginecología y Pediatría. Imprenta U. de Cartagena. Cartagena.1994; 241 250.
6 Sánchez Torres F. La anticoncepción. EN: Ciencia y reproducción humana. Empresa editorial Universidad Nacional de Colombia. Bogotá. 1991; 83 99.
7 Speroff J. Clinical Gynecologic endocrinology and infertility. Sixth Edition. 1999; Lippincott Williams & Wilkins.
8 Pincus G, Rock J, Garcia CR, et al. Fertility control with oral medication. Am J Obstet Gynecol. 1958; 75: 1333 1346.
9 Petterson CM. Progestágenos, antagonistas de la progesterona, y andrógenos: síntesis, clasificación y uso. Clínicas Obstétricas y Ginecológicas. 1995; 4: 783 790.
10 American Society for Reproductive Medicine. The Practice Committee of the American Society for Reproductive Medicine. Hormonal contraception: recent advances and controversies. Fertil Steril. 2004; 82(2): 520 526.
11 Kaunitz AM. Enhancing oral contraceptive success: the potential of new formulations. Am J Obstet Gynecol. 2004; 190 (suppl): S23 S29.
12 Jones KP. Oral contraception: current use and attitudes. Contraception. 1999; 59 (suppl): S17 – S20.
13 Bagshaw S. The combined oral contraceptives. Risk and adverse effects in perspective. Drug-Saf. 1995; 12 (2): 91 – 96.
14 American Collage of Obstetricians and Gynecologist. Hormonal contraception. ACOG technical bulletin Nº. 198 – October de 1994 Int J Gynaecol Obstet. 1995; 48 (1): 115 – 126.
15 Spona J, Elstein M, Feichtinger W. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996; 54 (2): 71- 77.
16 Bachmann G, Sulak P, Sampson-Landers C, et al. Efficacy and safety of a low dose 24-day combined oral contraceptive containing 20 ug etinilestradiol and 3 mg drospirenone. Contraception. 2004: 70: 191 198.
17 OMS. Medical eligibility criteria for contraceptive use. 3° edition. 2004.
18 Carter CJ. Oral contraceptives and thrombosis. Curr Opin Pulm Med. 2000; 6(4): 296 – 300.
19 Word Health Organization. Cardiovascular disease and steroid hormone Contraception. Report of a WHO scientific Group. World Health Organ Tech Rep Ser. 1998; 877: 1 – 89.
20 Thorogood M, Vessey MP. Trends in use of oral contraceptives in Britain. Br J Fam. 1990; 16: 41 – 53.
21 Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and oral contraceptives: A review. Contraception. 1995; 52: 137 – 141
22 Ojeda G, Ordoñez M, Ochoa L. Salud Sexual y Reproductiva en Colombia. Encuesta Nacional de Demografía y Salud. ENDS-2000.
Colombia. Profamilia. Bogotá 2000.
23 Willekes C, Hoogland HJ, Keiser HA, et al. Three months use of third generation oral contraceptives does not affect artery wall properties.
Ultrasound Med Biol. 1999; 25(5): 723 – 728.
24 Grant ECG. Dangers of suppressing menstruation. Lancet. 2000; 356: S13.
25 Archer D. New Contraceptive options. Clinical Obstet and Gynecol. 2001; 44(1): 122 126.
26 Ferguson H, Vree ML, Wilpshaar J, et al. Multicenter study of the efficacy, cycle control and tolerability of a triphasic desogestrel containing oral contraceptive. Eur J Contracep Reprod Health Care. 2000; 5(1): 35 – 45.
27 Coata G, Ventura F, Lombardini R, et al. Effect of low dose oral Tripasic contraceptives on blood viscosity, coagulation and lipid metabolism. Contraception. 1995; 52: 151 157.
28 Rowan JP. Estrophasic dosing: A new concept in oral contraceptive therapy. Am J Obstet Gynecol. 1999; 180 (2 pt2): 302 – 306.
29 Anderson FD, Hait H. Seasonale 301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003; 68: 89 96.
30 Andrist LC, Arias RD, Nucatola D. Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception. 2004; 70(5): 359 363.
31 Gestodene Study Group. 322. The safety and contraceptive efficacy of a 24 day low dose oral contraceptive regimen containing Gestodene 60 ug and Ehinyl estradiol 15 ug. Eur J Contracep Reprod Health Care. 1999; 4(suppl 2): 9 – 15.
32 Gestodene Study Group. 324. Cycle control, safety and efficacy of a 24 Day regimen of Gestodene 60 ug/ethinylestradiol 15 ug and a 21 day regimen of Desogestrel 150 ug/ ethinylestradiol 20 ug. Eur J Contracep Reprod Health Care. 1999; 4(suppl 2): 17 – 25.
33 Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparation. Drug. 1995; 50 (2): 364 – 395.
34 Lete I, Morales P. Inhibition of follicular growth by two different oral contraceptives (monophasic and triphasic) containing ethinyl Estradiol and Gestodene. Eur J Contracept Reprod Health Care. 1997; 2(3): 187 191.
35 Coney P, Del Conte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 micrograms Levonorgestrel and 20 micrograms ethinyl Estradiol. Am J Obstet Gynecol. 1999; 181 (5pt 2): 53 – 58.
36 Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraception and intrauterine contraceptive device. Am J Obstet Gynecol. 1999; 181(5 pt 1): 1263 – 1269.
37 Sullivan H, Furniss H, Spona J. Effects of 21- day and 24 – day oral contraceptive regimens containing gestodene (60 ug) and Ethinyl Estradiol (15 ug) an ovarian activity. Fertil Steril. 1999; 72(1): 115 – 120.
38 Spona J, Feichtinger W, Kinderman C, et al. Double – bind Randomized, placebo controlled study in the effects of the monophasic oral contraceptive containing 30 ug EE and 2 mgs de Dienogest on the hemostatic system. Contraception. 1997; 56(2): 67 – 75.
39 Spona J, Feichtinger W, Kinderman C, et al. Modulation of ovarian function by en oral contraceptive containing 30 ug Ethinyl Estradiol in combination with 2 mg Dienogest. Contraception. 1997; 56(3): 185 – 191.
40 Speroff L, Decherney A. Evolution of a new generation of oral contraceptive. Obstet Gynecol. 1993; 81: 1034 – 1047.
41 Winkler UH, Schindler AE, Endrikat J, et al. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptive containing 20 ug and 30 ug Etinil-Estradiol. Contraception. 1996; 53: 75 – 84.
42 Endrikat J, Jaques MA, Mayerhofer M, et al. A Twelve-month comparative clinical investigation of two low-dose oral Contraceptives containing 20 ug Ethinyl Estradiol / 75 ug Gestodene and 20 ug Ethinyl Estradiol / 150 ug Desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52: 229 235.
43 Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000; 27(4): 705 – 721.
44 Dusterberg B, Ellman H, Muller U et al. Three year’s clinical experience with a new low-dose oral contraceptive containing 20 ug ethinylestradiol and 75 ug gestodene: Efficay, cycle control and tolerability. IN: Lopes P, killick Sr (eds). The New option in low-dose oral contraception Expanding the Gestodene choice. Carnhorth, lancs, England: Parthenon publishing, 1996: 37
45 Short M, Endrikat J. A 12- month comparative investigation of reliability, cycle control and tolerance with low-dose oral contraceptives containing 20 ug ethinyl Estradiol and either 75 ug Gestodene or 150 ug Desogestrel. IN: Lopes P, killick Sr (eds). The New option in low-dose oral contraception Expanding the Gestodene choice. Carnhorth, lancs, England: Parthenon publishing, 1996: 47 57. 46 Huner A, Kuhnz W, Heger-mahn D, et al. A single dose and 3 month
clinical pharmacokinetic study with a new combination oral contraceptive. Advances in contraception. 1995; 11: 207 225.
47 Van Heusden AM, Fauester BC. Activity of the pituitary ovarian axis in the pill- free interval during use of low dose combined oral contraceptives. Contraception. 1999; 59(4): 237 – 243.
48 Boerrigter PJ, Ellman H, Dolker M. International clinical experience with a new low dose, monophasic oral contraceptive containing Levonorgestrel 100 microg and ethinyl Estradiol 20 microg. Clin Ther. 1999; 21(1): 118 – 127.
49 Reisman H, Martin D, Gast MJ, A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg Levonorgestrel with 20 microg ethinyl Estradiol or triphasic Norethindrone with ethinyl Estradiol. Am J Obstet Gynecol. 1999; 181 (5 pt 2): 45 – 52.
50 Thorneycroft IH, Stanczyk FZ, Bradshaw Kd, et al. Effect of low-dose oral contraceptive on androgenic markers and acne. Contraception. 1999: 60 (5): 255 – 262.
51 Rosing J, Middeldorp S, Curves J, et al. Low- dose oral contraceptives and acquired resistance to activated protein C: a randomized crossover study. Lancet. 1999; 354 (9195): 2036 – 2040.
52 Lawrenson R, Farmer R. Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference? Contraception. 2000; 62 (2 suppl): 21S – 28S.
53 Winkler UH. Hemostatic effects of third and second generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception. 2000; 62(2): (2 suppl): 11S – 20S.
54 Coenen CMH, Thomas CMG, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996; 53: 171 176.
55 Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks and benefits. Menopause. 2002; 9(1): 6 15.
56 Colli Capdevila C. Anticoncepción hormonal oral combinada: nuevos Gestágenos. EN: Pellicer A, Simon C. Cuadernos Medicina Reproductiva. 2001; 7 (2): 53 64.
57 Mercilon a new low dose combined oral contraceptive. DTB. 1989; 27: 51 – 52.
58 Cilest – a combined OC. DTB. 1991; 29: 103 – 104.
59 Fotherby K, Caldwell DS. New progestogen in oral contraception. Contraception. 1994; 49: 1 – 32.
60 Farmer RDT, Lawrenson R. Utilization patterns of oral contraceptives in UK General Practice. Contraception. 1996; 53: 211 215.
61 Jamin C, Mouzon J. Selective prescribing of third generation oral contraceptives. Contraception. 1996; 54: 55 56.
62 Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineral progestogen, drospirenone, on the rennin aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metabolism. 1995; 80: 1816 1821.
63 Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Molecular and cellular endocrinology. 2004; 217: 255 261.
64 Winkler UH. Gaspard U, Leidenbergar F. The influence of low-dose oral contraceptive containing 20 ug ethinyl Estradiol and 75 ug Gestodene on lipid and carbohydrate metabolism and hemostasis. IN: Lopes P, killick Sr (eds). The New option in low-dose oral contraception Expanding the Gestodene choice. Carnhorth, lancs, England: Parthenon publishing, 1996: 49 – 63.
65 Oosterbaan HP. An open – label study of the effects of a 24 day regimen of Gestodene 60 ug/ethinilestradiol 15 ug on endometrial histological findings in healthy women. Eur J Contracep Reprod Health Care. 1999; 4(suppl 2): 3 – 8.
66 Dorea JG. Oral contraceptives do not affect magnesium in breast milk. Int J Gynaecol Obstet. 2000; 7(1): 25 – 31.
67 Dorea JG, Myaazaki E. Calcium and phosphorus of Brazilian mothers using oral contraceptives. J Am coll Nutr. 1998: 17(6): 642 – 646.
68 Zimmermann T, Dietrich H, Wisser KH, et al. The efficacy and tolerability of Valette: a post marketing surveillance study. Eur J Contracep Reprod Health Care. 1999; 4(3): 155 164.
69 Rosenberg MJ, Waugh MS, Meehan T. Use and misuse of oral
contraceptives: risk indicators for poor pill taking and discontinuation. Contraception. 1995; 51: 283 – 288.
70 Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low dose oral contraceptives containing 20 micrograms ethinyl Estradiol and either 150 micrograms Desogestrel or 75 micrograms Gestodene. Eur J Contracept Reprod Health Care.
1998; 3(4): 179 189
71 Bruni V, Croxato H, De la cruz J, et al. A Comparison of cycle control and effect on well-being of monophasic Gestodene, triphasic Gestodene and monophasic Desogestrel containing oral
contraceptives. Gestodene Study Group. Gynecol Endocrinol. 2000; 14(2): 90 – 98.
72 Rosenberg MJ, Waugh MS, Higgins JE. The effect of Desogestrel, Gestodene and other factors on spotting and bleeding. Contraception. 1996; 53: 85 – 90.
73 Van der Mooren MJ, Klipping C, Aken B, et al. A comparative study of the efects of Gestodene 60 ug ethilestradiol 15ug and Desogestrel 150 ug ethinilestradiol 20 ug on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999; 4(suppl 2): 27 – 35.
74 Darney P. Safety and efficacy of a Tripasic oral contraceptive containing Desogestrel: results of three multicenter trial. Contraception. 1993; 48: 323 327.
75 Fiedman AJ. Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in pre menopausal women with leiomyomas? Obstet Gynecol. 1995; 85:
631 635.
76 Parsey KS, Pong A. An open label multicenter study to evaluated Yasmin, a low- dose combination oral contraceptive containing drosperinone, a new progestogen. Contraception. 2000; 61(2): 105 -111.
77 Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptives containing etinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000; 5(1): 25 – 34
78 Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation ofcontraceptive reliability, cycle control and tolerance of two monophasic oral contraceptive containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000; 5(2): 124 134.
79 Spinillo A, Capuzzo E, Nicola S, et al. The impact of oral contraception on vulvo vaginal candidiasis. Contraception. 1995; 51: 293 297.
80 Rechberger T, Baranowski W, Postawski K, et al. Serum leptin concentrations in women taking oral contraceptives. Eur J Obstet Gynecol Reprod Biol. 1999; 83(1): 105 – 108.
81 Grupo científico de la O.M.S. sobre anticonceptivos orales y neoplasias. Anticonceptivos orales y neoplasias. Informe de un grupo científico de la O.M.S. Informes técnicos 1992. No. 817: 1 -47.
82 Kaunitz AM. Oral contraceptive health benefits: perception versus reality. Contraception. 1999; 59 (1Suppl): 29S – 33S.
83 Balasch J, Calaf J. Riesgos de la contracepción hormonal (Con especial referencia a la enfermedad trombo – embolica) Clin Invest Gin Obstet. 1996; 23(4): 148 157.
84 Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence- based approach. Int J Fertil Women’s Med. 2000; 45(3): 241- 247.
85 Burkman R, Schlesselman J, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004; 190: S5 S22.
86 Dueñas Díez JL. Risks and benefits of oral contraceptives. Clínica e Investigación en Ginecología y Obstetricia. 1999: 26(4): 154 – 165.
87 Monterrosa A. Dismenorrea: Vision Actual. Rev. Colombiana de Ginecología y obstetricia. 2001; 52(4): 343 354.
88 Larsson G, Milson I, Lindstedt G, et al. The influence of a low dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992; 46: 327 334.
89 Monterrosa A. Dolor pélvico crónico: diagnóstico diferencial. Revista Selecta Médica. 1997; 8(1): 26 29.
90 Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database of Systematic Reviews. 1999; 3: 3.
91 Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004; 89: 2817 2823.
92 Lanes SF, Birmann B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol. 1992; 166: 956 961.
93 Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998; 339: 424 428.
94 Beck Jr. WW. Use oral Contraceptives in women in their 40S. Postgraduate Obstetrics Gynecology. 1995; 15 (12): 1 6.
95 Cancer and steroid hormone study. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med. 1987; 316: 650 – 655.
96 Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol. 1992; 80: 708 714.

Anterior Siguiente

DÉJANOS TU COMENTARIO

DÉJANOS TU COMENTARIO

Please enter your comment!